Need-to-know drugs in testing to treat COVID-19: New rundown

Test tube testing image
Drugmakers have put forward 14 repurposed meds as possible COVID-19 therapeutics. (Pixabay)

With the novel coronavirus continuing to spread around the globe, drugmakers of all sizes are on the hunt for a possible therapeutic for the crisis. One option? Evaluating older meds to determine whether they can be repurposed as a possible treatment for COVID-19.

Pharma's strategy for developing a therapeutic is being fought on two fronts: Repurposing existing meds—be they antivirals or anti-inflammatories or another option altogether—and developing investigational candidates to target COVID-19, the condition caused by the novel coronavirus, directly.

So far, 14 repurposed drugs are in researchers' hands, according to the World Health Organization and drugmaker reports. 

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

Take chloroquine, for example: The long-generic malaria med has captured the nation's attention after President Donald J. Trump highlighted its use alongside antibiotic Z-Pack (azithromycin) as a possible treatment for COVID-19. Alongside a suite of antivirals, two meds in the IL-6 inhibitor class, Sanofi and Regeneron's Kevzara and Roche's Actemra, have also been submitted for clinical trials. 

RELATED: Top COVID-19 aspirants chloroquine, AbbVie's Kaletra and a flu drug disappoint in clinical tests

So far, the results for those repurposed hopefuls have been mixed, at best.

Hydroxychloroquine, a more tolerable form of chloroquine, didn't top placebo at clearing the coronavirus among Chinese patients with mild cases, or at helping them reach normal temperature sooner, Evercore ISI analyst Umer Raffat noted in a Tuesday memo.

Separately, neither AbbVie's Kaletra, a combination of HIV antivirals lopinavir and ritonavir, nor Arbidol (umifenovir) delivered benefits in viral clearance or symptom relief compared with no antiviral treatment in a small Chinese study in mild-to-moderate COVID-19 patients, results published Monday on the preprint site medRxiv show.

RELATED: Roche pleads for global harmony as it supercharges production of Actemra, COVID-19 tests

With demand growing, though, drugmakers are stepping up to increase production. Earlier this week, Roche said it was "working urgently" to maximize production of Actemra to meet current demand while supplying clinical trials. The immunology med is in testing to treat the dangerous lung inflammation that hits patients with serious cases.

Meanwhile, AbbVie said it would waive patent rights for Kaletra to allow countries to buy cheaper generics of the drug and prevent a possible shortage. With no patent rights to enforce, AbbVie would likely forgo millions in profits if Kaletra is found effective to treat COVID-19. 

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.